Shanghai Fosun Pharmaceutical Group Co Ltd (600196) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others.

Total Revenue Chart for Shanghai Fosun Pharmaceutical Group Co Ltd

Shanghai Fosun Pharmaceutical Group Co Ltd (600196) revenue for FY2025 was CNY 41.5B, a 1.1% change from FY2024. Shanghai Fosun Pharmaceutical Group Co Ltd's revenue grew from CNY 64.7M in 1995 to CNY 41.5B in 2025 (64094.5% over 30 years). Earnings per share grew from CNY 0.07 in 2000 to CNY 1.43 in 2022 (1857.7%). Revenue compound annual growth rate: 5-year CAGR of 6.5%, 10-year CAGR of 12.7%, 20-year CAGR of 14.1%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.